Medtronic’s insulin pumps
Despite some troubles with older generations of its MiniMed insulin pumps, including recalls and potential legal action, the latest iterations have demonstrated successes in clinical trials, while Medtronic (NYSE:MDT) has also been active on the M&A front with eyes on diabetes management.
This autumn, the company has made one acquisition and is reportedly in advanced talks over another. In September, Medtronic announced the acquisition of intellectual property from the Alfred E. Mann Foundation. The IP was related to implanted infusion pumps and AMF will work with Medtronic to develop the technology into a next-generation implantable insulin pump for people living with hard-to-treat type 1 diabetes in Europe.
Additionally, last month, reports in Israel said Medtronic was in negotiations to buy Triple Jump, a startup based in Yokneam, Israel, that develops a small insulin pump patch placed on the patient’s body and designed to offer mobile connectivity. The deal was reportedly worth around $300 million and could see Triple Jump’s system included in an artificial pancreas in the future.
In October, the company also reported positive one-year, real-world clinical data for its MiniMed 780G insulin pump platform in children.